The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).
 
Michael Wang
Stock and Other Ownership Interests - More Health
Honoraria - AstraZeneca; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries; Onclive; oncology business review; Peerview; Pharmacyclics; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; AxImmune; Bioinvent; Celgene; Guidepoint Global; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Loxo; More Health; Noble Insights; Pharmacyclics/Janssen; Pulse Biosciences
Research Funding - Acerta Pharma; Amgen; AstraZeneca; BeiGene; Bioinvent; Celgene; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Loxo; Novartis; Oncternal Therapeutics; Pharmacyclics; VelosBio; Verastem
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries
 
Javier Munoz
Honoraria - Kyowa Hakko Kirin; Seagen
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Fosun Kite; Genentech; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Pfizer; Pharmacyclics; Seagen
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Andre Goy
Employment - Regional Cancer Care Associates
Leadership - COTA
Stock and Other Ownership Interests - COTA
Honoraria - AstraZeneca; AstraZeneca; OncLive Peer Exchange
Consulting or Advisory Role - Acerta Pharma; Celgene; Elsevier; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Janssen; Janssen; Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company; Medscape; MJH Associates; Physicans' Education Resource; Xcenda
Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); Infinity/Verastem (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kite/Gilead (Inst); Pharmacyclics (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Physicans' Education Resource
 
Frederick Lundry Locke
Consulting or Advisory Role - Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Calibr; Celgene; Cellular Biomedicine Group; Cowen; EcoR1 Capital; GammaDelta Therapeutics; Gerson Lehrman Group; Iovance Biotherapeutics; Legend Biotech; Novartis; WUGEN, Inc.
Research Funding - Alimera Sciences (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Caron A. Jacobson
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Humanigen; Kite/Gilead; Nkarta; Novartis; precision biosciences
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Humanigen; Kite/Gilead; Lonza; Nkarta; Novartis; Precision Biosciences
Speakers' Bureau - Axis Bioservices; Clinical Care Options
Research Funding - Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer
Travel, Accommodations, Expenses - Kite/Gilead; Novartis; Precision Biosciences
 
Brian T. Hill
Honoraria - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis; Novartis; Pfizer; Pharmacyclics
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Genentech (Inst); Karyopharm Therapeutics (Inst); Kite/Gilead (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
John Timmerman
Honoraria - Kite/Gilead
Consulting or Advisory Role - Celgene; Genmab; Kite/Gilead; Seagen
Research Funding - Bristol-Myers Squibb; ImmunGene; Kite, a Gilead company; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Houston Holmes
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Johnson & Johnson; Kite, a Gilead Company; Rigel
Speakers' Bureau - Kite, a Gilead Company; Rigel; Seagen
Research Funding - ADC Therapeutics; Bristol-Myers Squibb; Kite, a Gilead Company; Novartis; Roche; Seagen; Unum
Patents, Royalties, Other Intellectual Property - a pending patent
 
Samantha Jaglowski
Consulting or Advisory Role - crispr therapeutics; Juno Therapeutics; Kite/Gilead; Novartis
Research Funding - Kite/Gilead; Novartis; Unum Therapeutics
 
Ian Flinn
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Genentech (Inst); Gilead Sciences (Inst); Great Point Partners (Inst); Iksuda Therapeutics (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Novartis (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); Shanghai Yingli Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Curis (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Juno Therapeutics (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Loxo (Inst); Merck (Inst); MorphoSys (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Rhizen Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Teva (Inst); TG Therapeutics (Inst); Triact Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
 
Peter A. McSweeney
Honoraria - Kite, a Gilead Company
Consulting or Advisory Role - Kite, a Gilead Company
Speakers' Bureau - Kite, a Gilead Company
Research Funding - AlloVir; Autolus; Kite, a Gilead Company; Novartis
 
David Bernard Miklos
Consulting or Advisory Role - Adaptive Biotechnologies; Alimera Sciences; Janssen; Juno/Celgene; Kite, a Gilead company; Miltenyi Biotec; Novartis; Pharmacyclics; Precision Biosciences
Research Funding - Adaptive Biotechnologies; Alimera Sciences; Kite, a Gilead company; Novartis; Novartis; Pharmacyclics; Precision Biosciences; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Juno Therapeutics; Kite, a Gilead company; Miltenyi Biotec; Novartis; Pharmacyclics/Janssen
 
Marie José Kersten
Honoraria - Kite, a Gilead company; Novartis; Roche
Consulting or Advisory Role - Kite, a Gilead Company; Miltenyi Biotec (Inst); Novartis; Takeda (Inst)
Research Funding - Kite, a Gilead company (Inst)
Travel, Accommodations, Expenses - Celgene; Kite, a Gilead Company; Novartis; Roche
 
Krimo Bouabdallah
Honoraria - Roche; Takeda Science Foundation
Consulting or Advisory Role - Roche; Takeda
Travel, Accommodations, Expenses - Roche; Takeda
 
Max S. Topp
Consulting or Advisory Role - Amgen; Kite/Gilead; Kite/Gilead; Novartis; Regeneron; Roche
Research Funding - Boehringer Ingelheim (Inst); Kite, a Gilead company (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Celgene; Regeneron
 
Rhine Shen
Employment - Kite, a Gilead Company
 
Ioana Kloos
Employment - Kite, a Gilead Company
 
Weimin Peng
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Xiang Fang
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Patrick M. Reagan
Consulting or Advisory Role - Kite, a Gilead Company
Research Funding - Genentech; Seagen